Revenues Revenues (Tables)

3 Months Ended

Mar. 31, 2019

Revenues by product are summarized as follows:



	For the Three Months Ended March 31,
(In millions)	2019						2018
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
TECFIDERA	$	717.7	$	281.1	$	998.8	$	728.9	$	258.0	$	986.9
Interferon*	327.3		173.6		500.9		371.4		178.9		550.3
TYSABRI	245.0		215.4		460.4		249.7		212.4		462.1
FAMPYRA	—		22.9		22.9		—		24.4		24.4
ZINBRYTA	—		—		—		—		1.4		1.4
Subtotal: MS product revenues	1,290.0		693.0		1,983.0		1,350.0		675.1		2,025.1

Spinal Muscular Atrophy:
SPINRAZA	223.3		295.2		518.5		188.0		175.9		363.9

Biosimilars:
BENEPALI	—		124.0		124.0		—		120.9		120.9
FLIXABI	—		14.7		14.7		—		6.6		6.6
IMRALDI	—		35.7		35.7		—		—		—
Subtotal: Biosimilar product revenues	—		174.4		174.4		—		127.5		127.5

Other:
FUMADERM	—		4.1		4.1		—		7.0		7.0
Total product revenues	$	1,513.3	$	1,166.7	$	2,680.0	$	1,538.0	$	985.5	$	2,523.5

*Interferon includes AVONEX and PLEGRIDY.

An analysis of the change in reserves for discounts and allowances is summarized as follows:



(In millions)	Discounts			Contractual Adjustments			Returns			Total
Balance, as of December 31, 2018	$	127.8		$	888.8		$	34.7		$	1,051.3
Current provisions relating to sales in current year	141.2			680.3			4.7			826.2
Adjustments relating to prior years	0.3			(25.1		)	0.3			(24.5		)
Payments/credits relating to sales in current year	(60.8		)	(233.9		)	(0.1		)	(294.8		)
Payments/credits relating to sales in prior years	(92.1		)	(378.1		)	(4.6		)	(474.8		)
Balance, as of March 31, 2019	$	116.4		$	932.0		$	35.0		$	1,083.4

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:



(In millions)	As of March 31, 2019		As of December 31, 2018
Reduction of accounts receivable, net	$	175.8	$	176.6
Component of accrued expenses and other	907.6		874.7
Total revenue-related reserves	$	1,083.4	$	1,051.3

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Three Months Ended March 31,
(In millions)	2019		2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA	$	390.8	$	349.6
Other revenues from anti-CD20 therapeutic programs	126.6		93.6
Total revenues from anti-CD20 therapeutic programs	$	517.4	$	443.2

Other revenues are summarized as follows:



	For the Three Months Ended March 31,
(In millions)	2019			2018
Revenues from collaborative and other relationships:
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie	$	(0.4	)	$	(4.7	)
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis	24.8			17.9
Other royalty and corporate revenues:
Royalty	3.9			10.6
Other corporate	264.1			140.6
Total other revenues	$	292.4		$	164.4